Craft

SpringWorks Therapeutics

Stock Price

$30.1

2024-10-29

Market Capitalization

$2.2 B

2024-10-29

Revenue

$191.6 M

FY, 2024

SpringWorks Therapeutics Summary

Company Summary

Overview
SpringWorks Therapeutics is a mission-driven medicines company dedicated to developing innovative potential new treatments for unserved and underserved patient communities.  The company connects scientists, biopharmaceutical partners, patient groups, funders and philanthropists to deliver promising, transformative science to underserved patients.
Type
Public
Status
Active
Founded
2017
HQ
Stamford, CT, US | view all locations
Website
http://www.springworkstx.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Saqib Islam

    Saqib Islam, Chief Executive Officer, Director

    • Daniel S. Lynch

      Daniel S. Lynch, Chairman

      • Alan Fuhrman

        Alan Fuhrman, Director

        • Francis Perier

          Francis Perier, Chief Financial Officer

          Operating MetricsView all

          Phase I Trials Products

          2

          FY, 2019

          Phase II Trials Products

          1

          FY, 2019

          Phase III Trials Products

          1

          FY, 2019

          LocationsView all

          2 locations detected

          • Stamford, CT HQ

            United States

            100 Washington Blvd

          • Durham, NC

            United States

            5310 S Alston Ave

          SpringWorks Therapeutics Financials

          Summary Financials

          Revenue (Q1, 2025)
          $49.1M
          Gross profit (Q1, 2025)
          $45.6M
          Net income (Q1, 2025)
          ($83.2M)
          Cash (Q1, 2025)
          $63.8M
          EBIT (Q1, 2025)
          ($80.5M)
          Enterprise value
          $2.2B

          Footer menu